The global veterinary CRO (Contract Research Organization) and CDMO (Contract Development and Manufacturing Organization) market is experiencing robust expansion. Valued at USD 7.17 billion in 2024, the market is expected to grow to USD 7.77 billion in 2025 and is projected to reach approximately USD 16.13 billion by 2034, at a CAGR of 8.43% during 2025–2034.
This growth is fueled by rising pet ownership, heightened demand for animal healthcare, and increasing outsourcing by pharmaceutical companies aiming for cost efficiency and regulatory compliance. Technological advancements and expanding veterinary clinical trials further support this upward trajectory.
Market Size (2024): USD 7.17 billion
Projected Size (2034): USD 16.13 billion
CAGR (2025-2034): 8.43%
North America Share (2024): 40–45%
Fastest Growing Region: Asia-Pacific
Dominant Service Type (2024): Contract Manufacturing Services (Oral dosage forms lead with 28–32% share)
Top Product (2024): Pharmaceuticals (38–42% market share)
Leading Animal Segment: Companion Animals (Dogs sub-segment holds 30–40% revenue share)
About: Argenta is a leading global veterinary CRO and CDMO specializing in end-to-end animal health solutions. Headquartered in New Zealand, it provides R&D, manufacturing, and clinical trial services.
Products: Veterinary pharmaceuticals, biologicals, and nutritional products.
Market Cap: Estimated privately held with annual revenues exceeding USD 200 million.
About: Aurigon Life Science offers contract research and regulatory services tailored for veterinary pharmaceuticals. It serves global animal health companies with a focus on regulatory compliance.
Products: Toxicology, bioanalytics, and regulatory affairs services.
Market Cap: Privately owned, with significant European market presence.
About: A division of Avacta Group, this UK-based company specializes in diagnostics and therapeutic development for animal health.
Products: Immunodiagnostic tests, allergy testing kits, and therapeutic antibodies.
Market Cap: Approx. USD 200–250 million (Avacta Group plc).
About: This global CRO giant offers a dedicated veterinary division providing preclinical and clinical support for animal health products.
Products: Safety assessment, bioanalysis, and veterinary clinical trial management.
Market Cap: ~USD 12 billion (NYSE: CRL).
About: Part of Elanco Animal Health, it offers contract manufacturing solutions for veterinary pharmaceuticals worldwide.
Products: Vaccines, oral medications, and injectable drugs for companion and livestock animals.
Market Cap: ~USD 10 billion (NYSE: ELAN).
About: Lonza’s veterinary biologics division provides contract development and manufacturing services for complex veterinary biologics.
Products: Veterinary vaccines, monoclonal antibodies, and advanced therapies.
Market Cap: ~USD 30 billion (SIX: LONN).
About: Huvepharma is a global pharmaceutical company with a strong focus on animal health and nutrition products.
Products: Antimicrobials, anticoccidials, and nutritional supplements.
Market Cap: Estimated at USD 1.5 billion (private company).
About: A well-known animal health company offering CDMO services in addition to its extensive veterinary product line.
Products: Veterinary vaccines, medicated feed additives, and nutritional specialty products.
Market Cap: ~USD 1.1 billion (NASDAQ: PAHC).
Increased Outsourcing: Pharmaceutical companies prefer CRO/CDMOs for cost-effective R&D and manufacturing.
Growth in Biologics: Rising demand for veterinary biologics like vaccines and monoclonal antibodies.
Digital Integration: Use of AI and big data in veterinary clinical trials.
APAC Expansion: Rapid growth in Asia-Pacific due to increasing pet care spending and livestock farming.
Request a customized case study tailored to your business needs and gain deeper insights
into healthcare market strategies: sales@towardshealthcare.com
Increased pet ownership, rising zoonotic disease concerns, and pharmaceutical outsourcing to enhance efficiency are key drivers.
North America leads the market with over 40% share in 2024, while Asia-Pacific is the fastest-growing region.
Contract manufacturing services dominate, with oral dosage forms being the largest sub-segment.
Argenta, Charles River Laboratories, Lonza, Huvepharma, and Phibro Animal Health are among the top companies.
The market is expected to grow at a CAGR of 8.43% from 2025 to 2034.
Source : https://www.towardshealthcare.com/insights/veterinary-cro-and-cdmo-market-sizing
Invest in Our Premium Strategic Solution: https://www.towardshealthcare.com/price/5873
The global digital health and wellness market is projected to expand from US$ 498.99 billion in 2024 to US$ 3,568.11… Read More
The global radiopharmaceutical market is projected to grow from USD 6.8 billion in 2024 to USD 14.11 billion by 2034,… Read More
The U.S. life science market is on an upward trajectory, poised to generate substantial revenue growth, potentially climbing into the… Read More
The U.S. cell therapy market size is forecast to grow at a CAGR of 21.46%, from USD 8.04 billion in… Read More
The global animal biotechnology market was USD 28.17 billion in 2024, rose to USD 30.97 billion in 2025, and is… Read More
The global ophthalmology devices market was US$ 7.51 billion in 2024, rose to US$ 7.89 billion in 2025, and is… Read More